Nova Mentis Life Science
Market Cap
CA$13.4m
Last Updated
2020/11/26 23:27 UTC
Data Sources
Company Financials
Executive Summary
Nova Mentis Life Science Corp. intends to produce medical marijuana in Canada. More Details
Snowflake Analysis
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Nova Mentis Life Science's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NOVA is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 21% a week.
Volatility Over Time: NOVA's weekly volatility has decreased from 28% to 21% over the past year, but is still higher than 75% of Canadian stocks.
Market Performance
7 Day Return
15.6%
NOVA
9.2%
CA Pharmaceuticals
2.8%
CA Market
1 Year Return
30.0%
NOVA
14.8%
CA Pharmaceuticals
-0.3%
CA Market
Return vs Industry: NOVA exceeded the Canadian Pharmaceuticals industry which returned 13.1% over the past year.
Return vs Market: NOVA exceeded the Canadian Market which returned -0.5% over the past year.
Shareholder returns
| NOVA | Industry | Market | |
|---|---|---|---|
| 7 Day | 15.6% | 9.2% | 2.8% |
| 30 Day | 40.5% | 30.1% | 10.0% |
| 90 Day | 62.5% | 29.9% | 5.7% |
| 1 Year | 30.0%30.0% | 14.8%14.8% | 3.3%-0.3% |
| 3 Year | -75.9%-75.9% | -31.8%-32.9% | 12.2%1.3% |
| 5 Year | 85.7%85.7% | 268.2%265.3% | 49.1%26.2% |
Long-Term Price Volatility Vs. Market
How volatile is Nova Mentis Life Science's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 months ago | Simply Wall St
Is Liberty Leaf Holdings (CSE:LIB) In A Good Position To Invest In Growth?8 months ago | Simply Wall St
Is Liberty Leaf Holdings (CSE:LIB) In A Good Position To Deliver On Growth Plans?1 year ago | Simply Wall St
We're Hopeful That Liberty Leaf Holdings (CNSX:LIB) Will Use Its Cash WiselyValuation
Is Nova Mentis Life Science undervalued compared to its fair value and its price relative to the market?
2.22x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate NOVA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate NOVA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: NOVA is unprofitable, so we can't compare its PE Ratio to the CA Pharmaceuticals industry average.
PE vs Market: NOVA is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NOVA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NOVA is overvalued based on its PB Ratio (2.2x) compared to the CA Pharmaceuticals industry average (1.5x).
Next Steps
Future Growth
How is Nova Mentis Life Science forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
60.5%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Nova Mentis Life Science has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Examine Nova Mentis Life Science's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Nova Mentis Life Science competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
Past Performance
How has Nova Mentis Life Science performed over the past 5 years?
-18.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NOVA is currently unprofitable.
Growing Profit Margin: NOVA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NOVA is unprofitable, and losses have increased over the past 5 years at a rate of 18.8% per year.
Accelerating Growth: Unable to compare NOVA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NOVA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-45%).
Return on Equity
High ROE: NOVA has a negative Return on Equity (-101.09%), as it is currently unprofitable.
Next Steps
Financial Health
How is Nova Mentis Life Science's financial position?
Financial Position Analysis
Short Term Liabilities: NOVA's short term assets (CA$1.4M) exceed its short term liabilities (CA$262.0K).
Long Term Liabilities: NOVA has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: NOVA is debt free.
Reducing Debt: NOVA has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NOVA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: NOVA has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 14.6% each year.
Next Steps
Dividend
What is Nova Mentis Life Science current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NOVA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NOVA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NOVA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NOVA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NOVA's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.4yrs
Average management tenure
CEO
Will Rascan
8.5yrs
Tenure
CA$170,000
Compensation
Mr. William Rascan, also known as Will, has been the Chief Executive Officer of Nova Mentis Life Science Corp. (formerly known as Liberty Leaf Holdings Ltd.). (formerly known as Weststar Resources Corp.) s...
CEO Compensation Analysis
Compensation vs Market: Will's total compensation ($USD0.00) is below average for companies of similar size in the Canadian market ($USD166.12K).
Compensation vs Earnings: Will's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 8.5yrs | CA$170.00k | 1.47% CA$ 197.2k | |
| Chief Financial Officer | 3.42yrs | CA$33.50k | no data | |
| COO & Director | 0.17yr | no data | no data | |
| Corporate Administrator | no data | no data | no data | |
| President & Chief Scientific Officer of Nova Mentis Biotech Corp. | no data | no data | 9.01% CA$ 1.2m |
3.4yrs
Average Tenure
Experienced Management: NOVA's management team is considered experienced (3.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 8.5yrs | CA$170.00k | 1.47% CA$ 197.2k | |
| COO & Director | 0.17yr | no data | no data | |
| Independent Director | 8.5yrs | CA$56.50k | 0.32% CA$ 43.4k | |
| Advisory Board Chair | 3.25yrs | no data | no data | |
| Member of Advisory Board | 3.08yrs | no data | no data | |
| Member of Advisory Board | 2.75yrs | no data | no data | |
| Member of Advisory Board | 2.5yrs | no data | no data |
3.1yrs
Average Tenure
Experienced Board: NOVA's board of directors are considered experienced (3.1 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 89.5%.
Top Shareholders
Company Information
Nova Mentis Life Science Corp.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Nova Mentis Life Science Corp.
- Ticker: NOVA
- Exchange: CNSX
- Founded: 2004
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$13.394m
- Shares outstanding: 60.88m
- Website: https://www.novamentis.ca
Location
- Nova Mentis Life Science Corp.
- 700-838 West Hasting Street
- Vancouver
- British Columbia
- V6C 0A6
- Canada
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| HN3Q | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Sep 2006 |
| LIBF.F | OTCPK (Pink Sheets LLC) | Yes | Common Shares | US | USD | Sep 2006 |
| NOVA | CNSX (Canadian National Stock Exchange) | Yes | Common Shares | CA | CAD | Sep 2006 |
Biography
Nova Mentis Life Science Corp. intends to produce medical marijuana in Canada. The company was formerly known as Liberty Leaf Holdings Ltd. and changed its name to Nova Mentis Life Science Corp. in June 20...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/11/26 23:27 |
| End of Day Share Price | 2020/11/26 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.